Cipla has applied for permission from DCGI to market Favipiravir in India as an experimental medicine for COVID-19. Under the guidances of ICMR, Cipla will also conduct a suitable limited trial prior to marketing the product as Ciplenza.
source https://www.pharmatutor.org/pharma-news/2020/cipla-seeks-approval-to-launch-experimental-covid-19-drug
No comments:
Post a Comment